BeOne Medicines Ltd. (ONC) Stock Price & How to Invest

Last updated November 2026

Short answer

ONC is BeOne Medicines, the Swiss-domiciled global oncology company formerly called BeiGene, whose Nasdaq security is an American Depositary Share representing 13 ordinary shares. Exposure comes from buying the ADS directly, or from holding it inside a cancer-therapeutics or China-linked biotech grouping alongside the large-cap oncology franchises it competes with.

ONC stock price

As of 2026-11-16, BeOne Medicines Ltd. (ONC) last closed at $411.29, up 9.2% over the past year. Over the past 52 weeks it has traded between $260.27 and $424.00.

ONC last close
$411.29
1 day
-1.26%
1 month
+11.44%
1 year
+9.20%
52-week range
$260.27 to $424.00
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or BeOne Medicines Ltd.'s investor relations page. Walnut is informational, not investment advice.

ONC key stats

At $411.29 on November 16, 2026, BeOne Medicines Ltd. (ONC) has a market cap of $47.0B and a P/E of 52.7 on trailing earnings (38.1 on forward earnings).

Market cap
$47.0B
P/E (trailing)
52.7
P/E (forward)
38.1
EPS (trailing 12 months)
$7.80
Price to book
8.1
Beta
0.63

Market cap, P/E and yield are measured at the $411.29 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with BeOne Medicines Ltd. (ONC)?

The last two weeks for BeOne Medicines Ltd., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ONC closed at $411.29 on November 16, 2026, down 1.4% over the past five trading days (from $417.33).
  • On November 5, 2026, BeOne Medicines Ltd. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, BeOne Medicines Ltd. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 6, 2026, RBC Capital raised its target to $465.00 from $459.00 (Outperform).
  • On November 6, 2026, Truist Securities raised its target to $448.00 from $420.00 (Buy).
  • On November 6, 2026, Barclays raised its target to $446.00 from $415.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

BeOne Medicines Ltd. (ONC) latest quarter

BeOne Medicines reported revenue of $1.9 billion for Q3 2026, up 34% from a year earlier (BeOne Medicines, Nov 5, 2026).

Revenue
$1.9 billion
up 34% from a year earlier
Diluted EPS (GAAP)
$3.28
up 201% from a year earlier
BRUKINSA
$1.4 billion
up 34% from a year earlier

Source: BeOne Medicines Q3 2026 results, Nov 5, 2026. Full earnings breakdown

What does BeOne Medicines Ltd. (ONC) do?

BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235).

The investment picture is a biotech that has finished crossing into profit. Trailing twelve-month revenue of ~$6.13 billion came with ~$656 million of GAAP net income after years of losses, and management raised 2026 revenue guidance to $6.6 billion to $6.8 billion with GAAP operating income of $1.0 billion to $1.1 billion. Second-quarter gross margin reached 90% of product sales, free cash flow was ~$435 million, and the balance sheet holds ~$5.28 billion of cash against ~$1.07 billion of debt. The argument is over what that stream is worth at roughly 6.8 times trailing sales and about 66 times trailing GAAP earnings (about 36 times forward estimates) as of October 16, 2026, when the ADS closed near $368, up about 18% year to date and close to its 52-week high of about $385. Supporters cite BRUKINSA taking share from Imbruvica and Calquence, a revenue base now ~54% U.S. and only ~30% China, and a deep internally discovered pipeline. Skeptics cite dependence on a single molecule, an AbbVie trade secret suit that survived dismissal, and a company whose research, manufacturing and selling straddle two governments rewriting the rules on each other.

Two policy items landed on August 31, 2026. BeOne announced a voluntary agreement with the U.S. government under which it joins the GENEROUS Medicaid model and commits to pricing future FDA-approved products in line with other key developed markets, and an onshoring agreement that secured an exemption from Section 232 pharmaceutical tariffs. Alongside it, a $300 million expansion of the Hopewell, New Jersey site takes total U.S. manufacturing investment past $1 billion. The same day it released new Phase 3 survival data supporting ZIIHERA-containing regimens in first-line HER2-positive gastroesophageal cancer. Third-quarter results are expected around November 5, 2026, with consensus near $1.76 billion of revenue and $1.88 of EPS per ADS.

What's driving BeOne Medicines Ltd. (ONC)?

1. BRUKINSA taking share in B-cell cancers

BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. sales of ~$893 million growing at the same rate. The share is coming from older BTK inhibitors, principally AbbVie and Johnson & Johnson's Imbruvica and increasingly AstraZeneca's Calquence. Positive Phase 3 MANGROVE results in previously untreated mantle cell lymphoma and 78-month SEQUOIA follow-up in treatment-naive CLL feed first-line submissions the company has guided to in the second half of 2026.

2. Costs growing slower than revenue

Second-quarter revenue rose 30% while total GAAP operating expenses rose 13%, which turned ~$88 million of prior-year GAAP operating income into ~$325 million. SG&A fell to 35% of product sales from 41%, and gross margin improved to 90% as the mix tilted toward global BRUKINSA. Full-year GAAP operating income guidance was raised to $1.0 billion to $1.1 billion, roughly doubling the range given a year earlier.

3. A pipeline meant to outlive one molecule

BEQALZI (sonrotoclax) has now cleared FDA accelerated approval in relapsed or refractory mantle cell lymphoma, and tacabrutideg, the BTK degrader, has a potential Phase 2 submission guided for the second half of 2026. Solid tumor work includes BGB-43395 (CDK4 inhibitor), now in a Phase 3 first-line breast cancer study, plus the B7-H4 antibody-drug conjugate BG-C9074 and the GPC3 bispecific BGB-B2033, both slated to start registrational trials.

4. Revenue mix moving away from China

Second-quarter revenue split ~$914 million U.S., ~$506 million China, ~$209 million Europe and ~$76 million rest of world. Europe grew 37% and rest of world 114%, both faster than China's 17%, of which roughly 7 points came from a stronger renminbi. A company that started as a China biotech now books more than half its revenue in the United States, which changes both its regulatory profile and how the market frames its policy risk. The August 2026 onshoring agreement and Section 232 tariff exemption, backed by more than $1 billion of cumulative U.S. manufacturing investment, reduce one channel of that risk, at the cost of a commitment to price future U.S. launches in line with other developed markets.

What are the risks to BeOne Medicines Ltd. (ONC)?

Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to trade-status changes and U.S. or Chinese action against firms with large operations in both. The August 2026 pricing agreement exempts BeOne from Section 232 pharmaceutical tariffs but ties future U.S. launch prices to other developed markets, which could cap the upside on new products. The valuation, near 66 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue.

What is the BeOne Medicines Ltd. (ONC) forecast?

27 analysts publish price targets on ONC, averaging $462.19 as of November 2026, or +12.4% against the $411.29 share price on November 16, 2026. The published targets run from $385.00 to $561.30, a moderate spread, and the ratings split 26 buy, 1 hold, 0 sell. Over the last six months there have been 11 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ONC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ONC a buy or a sell?

We give no verdict on BeOne Medicines Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. BRUKINSA taking share in B-cell cancers. BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. The most optimistic published target, $561.30, assumes this works close to its best case.

The case against. Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. The most pessimistic target, $385.00, is roughly what ONC is worth if this bites instead.

Read the full bull and bear case on ONC, including what would have to change to break either one. Walnut is not an investment adviser.

Has BeOne Medicines Ltd. (ONC) split its stock?

No. BeOne Medicines Ltd. (ONC) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is BeOne Medicines Ltd. (ONC) valued?

Market cap, P/E and dividend yield at today's price are in the ONC key stats above. The business figures below come from BeOne Medicines Ltd.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$6.13B (Q2 2026 up ~30% YoY)
  • Q2 2026 revenue: ~$1.71B
  • GAAP net income (TTM): ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss)
  • Q2 2026 diluted EPS per ADS: ~$2.05 GAAP vs ~$1.63 estimate; ~$3.84 adjusted
  • Q3 2026 consensus (~Nov 5): ~$1.76B revenue, ~$1.88 EPS per ADS

As of October 2026: Quarterly figures come from the Form 10-Q for the quarter ended June 30, 2026 and the Q2 2026 earnings release; market figures are Yahoo Finance data as of October 16, 2026. At about $41.9 billion, the ADS trades near 6.8 times trailing sales and 66 times trailing GAAP earnings, but about 36 times the forward estimate, since analysts expect EPS per ADS to reach roughly $7.64 in 2026 and $10.25 in 2027. Per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.

Which ETFs hold BeOne Medicines Ltd. (ONC)?

If you want ONC exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in ONCExpense ratio
FBTFirst Trust NYSE Arca Biotechnology Index Fund3.74%0.55%

Who competes with BeOne Medicines Ltd. (ONC)?

BTK and BCL2 inhibitors in hematology

The franchise BRUKINSA is displacing: Imbruvica (ibrutinib) from AbbVie and Johnson & Johnson, Calquence (acalabrutinib) from AstraZeneca, and Jaypirca (pirtobrutinib) from Eli Lilly in the post-BTK setting. BEQALZI (sonrotoclax) goes up against Venclexta (venetoclax), sold by AbbVie and Roche. These are the head-to-head fights that decide BeOne's largest revenue line.

Checkpoint inhibitors and large-cap oncology

TEVIMBRA competes with Merck's Keytruda, Bristol Myers Squibb's Opdivo, Roche's Tecentriq and AstraZeneca's Imfinzi, all with far larger installed positions in solid tumors. In China the PD-1 field is crowded further by Innovent, Junshi Biosciences, Hengrui and Akeso, which is part of why checkpoint pricing there is so much lower than in the U.S.

China-origin biotechs going global

Hengrui Pharmaceuticals, Innovent Biologics, Akeso, Zai Lab and Legend Biotech are pursuing the same path of discovering in China and commercializing worldwide. BeOne is the furthest along on revenue and is the reference case investors use when pricing the others, so sentiment toward the group tends to move together.

What stocks are similar to BeOne Medicines Ltd. (ONC)?

Other names that sit close to ONC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in BeOne Medicines Ltd. (ONC)

There are three common ways to get ONC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ONC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ONC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on BeOne Medicines Ltd. (ONC)

A newly profitable oncology company growing ~30% on the strength of one dominant BTK inhibitor, priced in October 2026 at roughly 6.8 times sales and 36 times forward earnings after a U.S. pricing and onshoring agreement that took Section 232 pharmaceutical tariffs off the table, while still carrying real single-product and U.S.-China policy exposure.

More on BeOne Medicines Ltd. (ONC)

Whether ONC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ONC a buy or a sell?, and where the stock could go from here in the ONC stock forecast.

For income investors, whether ONC pays a dividend and how the payout looks is covered in does ONC pay a dividend? And to weigh ONC against a peer, read the full side-by-side comparisons: ONC vs ABBV and ONC vs JNJ.

Wondering how ONC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about BeOne Medicines Ltd.

Ask Walnut's AI anything about ONC and see how it fits what you own.

FAQ

What does BeOne Medicines do?

+

BeOne discovers, develops, manufactures and sells cancer medicines worldwide. Its lead product is BRUKINSA (zanubrutinib), a BTK inhibitor for B-cell blood cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. It also sells the PD-1 antibody TEVIMBRA, the BCL2 inhibitor BEQALZI, ZIIHERA in HER2-positive gastroesophageal cancer, and several in-licensed Amgen products in China.

How does BeOne make money?

+

Almost entirely from product sales. Net product revenue was ~$1.68 billion in the second quarter of 2026, of which BRUKINSA was ~$1.2 billion, TEVIMBRA ~$229 million and the Amgen in-licensed products ~$157 million. Other revenue, mostly collaboration income, was ~$25 million. Gross margin on product sales ran at 90% in the quarter.

What did BeOne report in its most recent quarter?

+

For the quarter ended June 30, 2026, total revenue was ~$1.71 billion, up 30% year over year, with GAAP operating income of ~$325 million and GAAP net income of ~$237 million. Diluted GAAP earnings were ~$2.05 per ADS and ~$3.84 on an adjusted basis. Free cash flow was ~$435 million, and full-year revenue guidance rose to $6.6 billion to $6.8 billion.

How is ONC valued right now?

+

At roughly $41.9 billion of market value on ~$6.13 billion of trailing revenue as of October 16, 2026, the ADS trades near 6.8 times sales, about 66 times trailing GAAP earnings and about 36 times forward estimates. Against the midpoint of 2026 revenue guidance the sales multiple is closer to 6.2 times. Cash of ~$5.1 billion against ~$2.05 billion of debt (Yahoo basis) brings enterprise value below market cap.

Does BeOne Medicines pay a dividend?

+

No. BeOne pays no dividend on its ordinary shares or its Nasdaq-listed ADSs. The company only reached full-year GAAP profitability in 2025 and is directing cash into research, late-stage trials and capacity, including a $300 million onshoring expansion of its Hopewell, New Jersey manufacturing and R&D campus. Any return here would have to come from the share price. That expansion brings total U.S. manufacturing investment above $1 billion.

What are the main risks with ONC?

+

BRUKINSA is roughly 70% of product revenue, so the business is exposed to one molecule. Zydus has filed an ANDA challenging certain BRUKINSA patents, and AbbVie's trade secret suit over the BTK degrader program survived dismissal in May 2026. About 30% of revenue plus significant manufacturing sit in China, exposing the company to U.S.-China policy shifts, although an August 2026 agreement secured an exemption from Section 232 pharmaceutical tariffs. The multiple assumes growth continues.

How would someone invest in ONC?

+

The Nasdaq-listed security is an American Depositary Share representing 13 ordinary shares, bought through any brokerage that handles U.S. equities. Some investors hold it on its own, others size it as one position inside a themed group covering cancer therapeutics or globalizing biotech, alongside the competitors it is taking share from. Walnut lets you set target weights and track the group against those targets.

What was BeOne's August 2026 agreement with the U.S. government?

+

Announced August 31, 2026, it has two parts. BeOne joined the GENEROUS Medicaid model and committed to pricing future FDA-approved products in line with other key developed markets, and it signed an onshoring agreement that secured an exemption from Section 232 pharmaceutical tariffs. A $300 million expansion in Hopewell, New Jersey brings its total U.S. manufacturing investment to more than $1 billion. The release did not give discount percentages.

How has ONC stock performed in 2026?

+

As of October 16, 2026, the ONC ADS closed near $368, up about 18% year to date, about 16% over three months and about 16% over the past year, with a 52-week range of roughly $254 to $385. The mean analyst target is about $436 across 27 analysts. Walnut is not an investment adviser, and none of this is a recommendation.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with BeOne Medicines Ltd.'s investor relations page or your broker before making investment decisions.